Neola Medical

Bifogade filer

“A Major Milestone” – CEO Hanna Sjöström in interview with Life Science Sweden

A Major Milestone CEO Hanna Sjöström In Interview With Life Science Sweden

Prenumeration

Kalender

	Est. tid*
2025-11-05	08:50	Kvartalsrapport 2025-Q3
2025-08-22	08:50	Kvartalsrapport 2025-Q2
2025-05-22	-	X-dag ordinarie utdelning NEOLA 0.00 SEK
2025-05-21	-	Årsstämma
2025-05-21	-	Kvartalsrapport 2025-Q1
2025-02-12	-	Bokslutskommuniké 2024
2024-11-06	-	Kvartalsrapport 2024-Q3
2024-08-15	-	Kvartalsrapport 2024-Q2
2024-05-23	-	X-dag ordinarie utdelning NEOLA 0.00 SEK
2024-05-22	-	Årsstämma
2024-05-22	-	Kvartalsrapport 2024-Q1
2024-02-14	-	Bokslutskommuniké 2023
2023-12-29	-	Extra Bolagsstämma 2023
2023-11-09	-	Kvartalsrapport 2023-Q3
2023-08-15	-	Kvartalsrapport 2023-Q2
2023-05-19	-	X-dag ordinarie utdelning NEOLA 0.00 SEK
2023-05-17	-	Årsstämma
2023-05-17	-	Kvartalsrapport 2023-Q1
2023-02-14	-	Bokslutskommuniké 2022
2022-11-10	-	Kvartalsrapport 2022-Q3
2022-09-27	-	Extra Bolagsstämma 2022
2022-08-16	-	Kvartalsrapport 2022-Q2
2022-05-20	-	X-dag ordinarie utdelning NEOLA 0.00 SEK
2022-05-19	-	Årsstämma
2022-05-19	-	Kvartalsrapport 2022-Q1
2022-02-15	-	Bokslutskommuniké 2021
2021-11-09	-	Kvartalsrapport 2021-Q3
2021-09-14	-	Extra Bolagsstämma 2021
2021-08-17	-	Kvartalsrapport 2021-Q2
2021-05-21	-	X-dag ordinarie utdelning NEOLA 0.00 SEK
2021-05-20	-	Årsstämma
2021-05-20	-	Kvartalsrapport 2021-Q1
2021-02-16	-	Bokslutskommuniké 2020
2020-11-11	-	Kvartalsrapport 2020-Q3

Kontakt

Hanna Sjöström

VD, Neola Medical
E-post: hanna.sjostrom@neolamedical.com

Media

CEO Hanna Sjöström (4)

Logotype

“A Major Milestone” – CEO Hanna Sjöström in interview with Life Science Sweden

2025-02-25 07:10:00

Neola Medical takes an important step forward in advancing neonatal care. After years of development, the company has received approval to initiate its first clinical study on preterm born babies—a key step in evaluating its continiuos lung monitoring device, Neola®, for this vulnerable patient group. In an interview with Life Science Sweden, CEO Hanna Sjöström discusses the significance of this milestone, what it means for the company, and how it supports Neola Medical’s strategy for entering the U.S. market, where Neola Medical sees significant potential for growth and impact in neonatal care.

Read the full interview here: Life Science Sweden interview with CEO Hanna Sjöström

About Neola Medical
Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode